欢迎访问《现代生物医学进展》编辑部！

目的：探讨亚胺培南与西司他丁联合去甲万古霉素对重症获得性下呼吸道感染患者治疗效果。方法：回顾性分析获得性下呼吸道感染患者70 例临床资料，其中36 例为观察组，采用亚胺培南与西司他丁联合去甲万古霉素治疗；其余34 例为对照组，采用哌拉西林与他唑巴坦联合左氧氟沙星沙星治疗。比较两组患者治疗7 天后的效果、症状缓解时间、治愈时间、住院花费及不良反应发生率。结果：观察组有效率高于对照组，差异有统计学意义（P<0.05）；观察组症状缓解时间及治愈时间较对照组短，但住院花费高于对照组，差异有统计学意义（P<0.05）；观察组不良反应发生率高于对照组，差异有统计学意义（P<0.05）。结论：亚胺培南与西司他丁联合去甲万古霉素对获得性下呼吸道感染患者治疗显著，但不良反应较多，需临床加以重视。

英文摘要:

Objective:To investigate the effect of imipenem/cilastatin combined with norvancomycin in treatment of ICU patients with severe lower respiratory tract infections.Methods:The clinical data of 70 cases with critically acquired lower respiratory tract infections were retrospectively analyzed. 36 cases were treated with imipenem/cilastatin combined with norvancomycin, which were considered as the observation group, the remaining 34 cases were pulled piperazine amoxicillin/tazobactam combined with levofloxacin gatifloxacin as the control group. After 7 days of treatment, the symptom relief time, cure time, hospitalization cost and adverse reactions were compared between the two groups.Results:The effective rate of the observation group was 91.67 %significantly higher than 70.59 % of the control group with statistical significance (P<0.05); the symptom relief and healing time period of the observation group were shorter than that of the control group, but the cost of hospitalization in the observation group was higher than the control group (P<0.05); the adverse reactions of the observation group was 22.22 % which was significantly higher than 11.76 % of the control group (P<0.05).Conclusion:The imipenem/cilastatin combined with norvancomycin in treatment of ICU patients with severe lower respiratory tract infection has markedly faster healing time, but it has the corresponding increase in hospital cost, more adverse reactions, and the clinical work need attention.

View Full Text View/Add Comment Download reader